Roche Holding AG
Roche Holding AG, commonly referred to as Roche, is a leading global healthcare company headquartered in Basel, Switzerland (CH). Founded in 1896, Roche has established itself as a pioneer in the pharmaceutical and diagnostics industries, focusing on innovative solutions for oncology, immunology, infectious diseases, and personalised medicine. With a strong presence in Europe, North America, and Asia, Roche is renowned for its commitment to research and development, producing unique products such as targeted therapies and advanced diagnostic tools. The company’s robust portfolio includes well-known medications like Herceptin and Avastin, which have transformed cancer treatment. Roche's dedication to innovation has earned it a prominent market position, consistently ranking among the top pharmaceutical companies globally. Its achievements in personalised healthcare and diagnostics underscore its role as a leader in advancing medical science and improving patient outcomes.
DitchCarbon Score
How does Roche Holding AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Roche Holding AG's score of 82 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Roche Holding AG's reported carbon emissions
In 2023, Roche Holding AG reported total greenhouse gas emissions of approximately 6,000,000 kg CO2e across all scopes. This includes about 240,266,000 kg CO2e from Scope 1, 98,480,000 kg CO2e from Scope 2, and around 5,978,508,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, aiming for a 70% reduction in absolute Scope 1 and 2 emissions by 2029, based on 2022 levels. Additionally, Roche is committed to a 22.5% reduction in Scope 3 emissions from specific categories, including fuel- and energy-related activities and business travel, within the same timeframe. Roche has also pledged to achieve net-zero emissions across its entire value chain by 2045. This long-term commitment includes a further reduction target of 90% for both Scope 1 and 2 emissions, as well as Scope 3 emissions, by 2045 from the 2022 baseline. The company is actively working towards these goals, with a focus on engaging 70% of its suppliers to adopt science-based targets by 2029. These initiatives reflect Roche's dedication to sustainability and its role in addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Roche Holding AG is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
